189 related articles for article (PubMed ID: 18250158)
41. STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.
Nagy ZS; LeBaron MJ; Ross JA; Mitra A; Rui H; Kirken RA
Mol Cancer; 2009 Aug; 8():67. PubMed ID: 19709433
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-9 induces tyrosine phosphorylation of insulin receptor substrate-1 via JAK tyrosine kinases.
Yin T; Keller SR; Quelle FW; Witthuhn BA; Tsang ML; Lienhard GE; Ihle JN; Yang YC
J Biol Chem; 1995 Sep; 270(35):20497-502. PubMed ID: 7544789
[TBL] [Abstract][Full Text] [Related]
43. Critical role of the membrane-proximal, proline-rich motif of the interleukin-2 receptor gammac chain in the Jak3-independent signal transduction.
Tsujino S; Miyazaki T; Kawahara A; Maeda M; Taniguchi T; Fujii H
Genes Cells; 1999 Jun; 4(6):363-73. PubMed ID: 10421845
[TBL] [Abstract][Full Text] [Related]
44. Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis.
Bauer JH; Liu KD; You Y; Lai SY; Goldsmith MA
J Biol Chem; 1998 Apr; 273(15):9255-60. PubMed ID: 9535918
[TBL] [Abstract][Full Text] [Related]
45. SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells.
Lundin Brockdorff J; Woetmann A; Mustelin T; Kaltoft K; Zhang Q; Wasik MA; Röpke C; Ødum N
Cytokine; 2002 Nov; 20(4):141-7. PubMed ID: 12543077
[TBL] [Abstract][Full Text] [Related]
46. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
47. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.
Johnston JA; Bacon CM; Finbloom DS; Rees RC; Kaplan D; Shibuya K; Ortaldo JR; Gupta S; Chen YQ; Giri JD
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8705-9. PubMed ID: 7568001
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.
Kim BH; Kim M; Yin CH; Jee JG; Sandoval C; Lee H; Bach EA; Hahm DH; Baeg GH
Br J Pharmacol; 2011 Sep; 164(1):106-18. PubMed ID: 21434883
[TBL] [Abstract][Full Text] [Related]
49. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
50. Convergence of signaling transduced by prolactin (PRL)/cytokine chimeric receptors on PRL-responsive gene transcription.
Ferrag F; Chiarenza A; Goffin V; Kelly PA
Mol Endocrinol; 1996 Apr; 10(4):451-60. PubMed ID: 8721989
[TBL] [Abstract][Full Text] [Related]
51. O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.
Freund P; Kerenyi MA; Hager M; Wagner T; Wingelhofer B; Pham HTT; Elabd M; Han X; Valent P; Gouilleux F; Sexl V; Krämer OH; Groner B; Moriggl R
Leukemia; 2017 Oct; 31(10):2132-2142. PubMed ID: 28074064
[TBL] [Abstract][Full Text] [Related]
52. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
53. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.
Chen M; Cheng A; Chen YQ; Hymel A; Hanson EP; Kimmel L; Minami Y; Taniguchi T; Changelian PS; O'Shea JJ
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6910-5. PubMed ID: 9192665
[TBL] [Abstract][Full Text] [Related]
54. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-2 family cytokines stimulate phosphorylation of the Pro-Ser-Pro motif of Stat5 transcription factors in human T cells: resistance to suppression of multiple serine kinase pathways.
Nagy ZS; Wang Y; Erwin-Cohen RA; Aradi J; Monia B; Wang LH; Stepkowski SM; Rui H; Kirken RA
J Leukoc Biol; 2002 Oct; 72(4):819-28. PubMed ID: 12377952
[TBL] [Abstract][Full Text] [Related]
56. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
57. Direct interaction between Kit and the interleukin-7 receptor.
Jahn T; Sindhu S; Gooch S; Seipel P; Lavori P; Leifheit E; Weinberg K
Blood; 2007 Sep; 110(6):1840-7. PubMed ID: 17554063
[TBL] [Abstract][Full Text] [Related]
58. Regulation of IL-2 signaling.
Higuchi M; Asao H; Tanaka N; Oda K; Takeshita T; Sugamura K
Leukemia; 1997 Apr; 11 Suppl 3():416-7. PubMed ID: 9209410
[TBL] [Abstract][Full Text] [Related]
59. Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3.
Chin H; Wakao H; Miyajima A; Kamiyama R; Miyasaka N; Miura O
Blood; 1997 Jun; 89(12):4327-36. PubMed ID: 9192755
[TBL] [Abstract][Full Text] [Related]
60. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
